About Tubulin beta-4B chain
Tubulin beta-4B chain (TUBB4B) is a protein
from Homo sapiens identified by UniProt accession
P68371, 445 residues long.
MolForge cross-references it against 0 known binders and
498 disease associations.
Target properties
| Protein name | Tubulin beta-4B chain |
| UniProt accession | P68371 |
| Gene | TUBB4B |
| Organism | Homo sapiens |
| Length | 445 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (2)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (498)
Diseases linked to this target (Open Targets).
- Leber congenital amaurosis with early-onset deafness · score 0.63
- non-small cell lung carcinoma · score 0.62
- head and neck squamous cell carcinoma · score 0.61
- breast cancer · score 0.61
- neoplasm · score 0.60
- breast carcinoma · score 0.60
- ovarian cancer · score 0.60
- breast neoplasm · score 0.60
- gout · score 0.59
- acute lymphoblastic leukemia · score 0.59
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P68371-F1 | alphafold | PREDICTED | 92.27 | — |
Amino-acid sequence (445 residues)
MREIVHLQAG QCGNQIGAKF WEVISDEHGI DPTGTYHGDS DLQLERINVY YNEATGGKYV PRAVLVDLEP GTMDSVRSGP FGQIFRPDNF VFGQSGAGNN WAKGHYTEGA ELVDSVLDVV RKEAESCDCL QGFQLTHSLG GGTGSGMGTL LISKIREEYP DRIMNTFSVV PSPKVSDTVV EPYNATLSVH QLVENTDETY CIDNEALYDI CFRTLKLTTP TYGDLNHLVS ATMSGVTTCL RFPGQLNADL RKLAVNMVPF PRLHFFMPGF APLTSRGSQQ YRALTVPELT QQMFDAKNMM AACDPRHGRY LTVAAVFRGR MSMKEVDEQM LNVQNKNSSY FVEWIPNNVK TAVCDIPPRG LKMSATFIGN STAIQELFKR ISEQFTAMFR RKAFLHWYTG EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEEGEFEEEA EEEVA
Explore Tubulin beta-4B chain with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets